N-acetylcysteine reduces COVID-19 risk: real-time meta-analysis of 26 studies (Version 4)
, Aug 2026
15th treatment shown to reduce risk in
February 2021, now with p = 0.000002 from 26 studies, recognized in 3 countries.
No treatment is 100% effective. Protocols
combine treatments.
6,600+ studies for
220+ treatments. c19early.org
|
Significantly lower risk is seen for mortality, hospitalization, progression, recovery, and cases. 13 studies from 13 independent teams in 10 countries show significant benefit.
Meta-analysis using the most serious outcome reported shows 24% [15‑32%] lower risk. Results are similar for Randomized Controlled Trials, higher quality studies, and peer-reviewed studies.
Results are very robust—in worst case exclusion sensitivity analysis 18 of 26 studies must be excluded before statistical significance is lost.
Control N-acetylcysteineN-acetylcys..
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. All data and sources to reproduce this analysis are in the appendix.
Other meta-analyses show significant improvement with N-acetylcysteine for mortality1,2.
Covid Analysis et al., Aug 2026, preprint, 1 author.